(RGNX) Regenxbio - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US75901B1070
Stock: Gene Therapy, Drug Candidates, Technology Platform
Total Rating 25
Risk 44
Buy Signal -1.12
| Risk 5d forecast | |
|---|---|
| Volatility | 96.4% |
| Relative Tail Risk | -6.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.88 |
| Alpha | 21.35 |
| Character TTM | |
|---|---|
| Beta | 1.704 |
| Beta Downside | 0.730 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.42% |
| CAGR/Max DD | -0.30 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: RGNX Regenxbio March 05, 2026
REGENXBIO Inc. (RGNX) is a clinical-stage biotechnology company developing gene therapies in the United States. The companys therapies aim to correct genetic defects by delivering functional genes to cells, a common approach in gene therapy.
RGNX utilizes its proprietary NAV Technology Platform, an adeno-associated virus (AAV) gene delivery system. AAV vectors are frequently used in gene therapy due to their safety profile and ability to infect both dividing and non-dividing cells.
Key pipeline candidates include ABBV-RGX-314 for various retinal diseases and RGX-202, currently in Phase III for Duchenne muscular dystrophy. The company also develops treatments for mucopolysaccharidosis types I and II, and neuronal ceroid lipofuscinosis type 2.
RGNX licenses its NAV Technology Platform to other companies, indicating a dual business model of internal drug development and technology commercialization. A collaboration with AbbVie Global Enterprises Ltd. extends the development of ABBV-RGX-314 internationally. To gain deeper insights into RGNXs market position and financials, further research on ValueRay is recommended.
Headlines to watch out for
- ABBV-RGX-314 clinical trial results impact future revenue
- Regulatory approval for pipeline drugs crucial for commercialization
- NAV Technology Platform licensing agreements drive recurring income
- Duchenne muscular dystrophy drug trial success boosts valuation
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -193.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA 9.78 > 1.0 |
| NWC/Revenue: 95.74% < 20% (prev 209.8%; Δ -114.0% < -1%) |
| CFO/TA -0.27 > 3% & CFO -124.0m > Net Income -193.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.8m) vs 12m ago 1.73% < -2% |
| Gross Margin: 52.88% > 18% (prev 0.50%; Δ 5.24k% > 0.5%) |
| Asset Turnover: 37.09% > 50% (prev 17.88%; Δ 19.21% > 0%) |
| Interest Coverage Ratio: -3.45 > 6 (EBITDA TTM -139.9m / Interest Expense TTM 45.0m) |
Altman Z'' -11.39
| A: 0.36 (Total Current Assets 281.3m - Total Current Liabilities 118.1m) / Total Assets 453.0m |
| B: -2.49 (Retained Earnings -1.13b / Total Assets 453.0m) |
| C: -0.34 (EBIT TTM -155.5m / Avg Total Assets 459.5m) |
| D: -3.22 (Book Value of Equity -1.13b / Total Liabilities 350.3m) |
| Altman-Z'' Score: -11.39 = D |
Beneish M -2.69
| DSRI: 0.60 (Receivables 26.4m/21.6m, Revenue 170.4m/83.3m) |
| GMI: 0.94 (GM 52.88% / 49.84%) |
| AQI: 1.22 (AQ_t 0.04 / AQ_t-1 0.04) |
| SGI: 2.05 (Revenue 170.4m / 83.3m) |
| TATA: -0.15 (NI -193.9m - CFO -124.0m) / TA 453.0m) |
| Beneish M-Score: -2.69 (Cap -4..+1) = A |
What is the price of RGNX shares?
As of March 15, 2026, the stock is trading at USD 9.38 with a total of 726,912 shares traded.
Over the past week, the price has changed by -0.92%, over one month by +7.26%, over three months by -38.03% and over the past year by +30.84%.
Over the past week, the price has changed by -0.92%, over one month by +7.26%, over three months by -38.03% and over the past year by +30.84%.
Is RGNX a buy, sell or hold?
Regenxbio has received a consensus analysts rating of 4.42.
Therefore, it is recommended to buy RGNX.
- StrongBuy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RGNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.8 | 196.6% |
| Analysts Target Price | 27.8 | 196.6% |
RGNX Fundamental Data Overview March 11, 2026
P/S = 3.083
P/B = 3.2546
P/EG = 0.26
Revenue TTM = 170.4m USD
EBIT TTM = -155.5m USD
EBITDA TTM = -139.9m USD
Long Term Debt = 65.2m USD (estimated: total debt 73.5m - short term 8.29m)
Short Term Debt = 8.29m USD (from shortTermDebt, last quarter)
Debt = 73.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.0m USD (from netDebt column, last quarter)
Enterprise Value = 368.9m USD (525.5m + Debt 73.5m - CCE 230.1m)
Interest Coverage Ratio = -3.45 (Ebit TTM -155.5m / Interest Expense TTM 45.0m)
EV/FCF = -2.92x (Enterprise Value 368.9m / FCF TTM -126.4m)
FCF Yield = -34.26% (FCF TTM -126.4m / Enterprise Value 368.9m)
FCF Margin = -74.15% (FCF TTM -126.4m / Revenue TTM 170.4m)
Net Margin = -113.8% (Net Income TTM -193.9m / Revenue TTM 170.4m)
Gross Margin = 52.88% ((Revenue TTM 170.4m - Cost of Revenue TTM 80.3m) / Revenue TTM)
Gross Margin QoQ = 80.46% (prev -107.9%)
Tobins Q-Ratio = 0.81 (Enterprise Value 368.9m / Total Assets 453.0m)
Interest Expense / Debt = 16.70% (Interest Expense 12.3m / Debt 73.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -122.8m (EBIT -155.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.38 (Total Current Assets 281.3m / Total Current Liabilities 118.1m)
Debt / Equity = 0.72 (Debt 73.5m / totalStockholderEquity, last quarter 102.7m)
Debt / EBITDA = -0.28 (negative EBITDA) (Net Debt 39.0m / EBITDA -139.9m)
Debt / FCF = -0.31 (negative FCF - burning cash) (Net Debt 39.0m / FCF TTM -126.4m)
Total Stockholder Equity = 188.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.19% (Net Income -193.9m / Total Assets 453.0m)
RoE = -103.1% (Net Income TTM -193.9m / Total Stockholder Equity 188.0m)
RoCE = -61.41% (EBIT -155.5m / Capital Employed (Equity 188.0m + L.T.Debt 65.2m))
RoIC = -56.76% (negative operating profit) (NOPAT -122.8m / Invested Capital 216.4m)
WACC = 12.32% (E(525.5m)/V(599.0m) * Re(12.20%) + D(73.5m)/V(599.0m) * Rd(16.70%) * (1-Tc(0.21)))
Discount Rate = 12.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.45%
[DCF] Fair Price = unknown (Cash Flow -126.4m)
EPS Correlation: 51.00 | EPS CAGR: 49.79% | SUE: -2.50 | # QB: 0
Revenue Correlation: 18.74 | Revenue CAGR: 8.66% | SUE: -1.79 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.28 | Chg7d=+0.161 | Chg30d=+0.161 | Revisions Net=-1 | Analysts=5
EPS current Year (2026-12-31): EPS=-2.22 | Chg7d=-0.041 | Chg30d=-0.152 | Revisions Net=-1 | Growth EPS=+41.0% | Growth Revenue=+43.9%
EPS next Year (2027-12-31): EPS=-1.88 | Chg7d=+0.103 | Chg30d=+0.077 | Revisions Net=-1 | Growth EPS=+15.3% | Growth Revenue=+27.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
P/B = 3.2546
P/EG = 0.26
Revenue TTM = 170.4m USD
EBIT TTM = -155.5m USD
EBITDA TTM = -139.9m USD
Long Term Debt = 65.2m USD (estimated: total debt 73.5m - short term 8.29m)
Short Term Debt = 8.29m USD (from shortTermDebt, last quarter)
Debt = 73.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.0m USD (from netDebt column, last quarter)
Enterprise Value = 368.9m USD (525.5m + Debt 73.5m - CCE 230.1m)
Interest Coverage Ratio = -3.45 (Ebit TTM -155.5m / Interest Expense TTM 45.0m)
EV/FCF = -2.92x (Enterprise Value 368.9m / FCF TTM -126.4m)
FCF Yield = -34.26% (FCF TTM -126.4m / Enterprise Value 368.9m)
FCF Margin = -74.15% (FCF TTM -126.4m / Revenue TTM 170.4m)
Net Margin = -113.8% (Net Income TTM -193.9m / Revenue TTM 170.4m)
Gross Margin = 52.88% ((Revenue TTM 170.4m - Cost of Revenue TTM 80.3m) / Revenue TTM)
Gross Margin QoQ = 80.46% (prev -107.9%)
Tobins Q-Ratio = 0.81 (Enterprise Value 368.9m / Total Assets 453.0m)
Interest Expense / Debt = 16.70% (Interest Expense 12.3m / Debt 73.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -122.8m (EBIT -155.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.38 (Total Current Assets 281.3m / Total Current Liabilities 118.1m)
Debt / Equity = 0.72 (Debt 73.5m / totalStockholderEquity, last quarter 102.7m)
Debt / EBITDA = -0.28 (negative EBITDA) (Net Debt 39.0m / EBITDA -139.9m)
Debt / FCF = -0.31 (negative FCF - burning cash) (Net Debt 39.0m / FCF TTM -126.4m)
Total Stockholder Equity = 188.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.19% (Net Income -193.9m / Total Assets 453.0m)
RoE = -103.1% (Net Income TTM -193.9m / Total Stockholder Equity 188.0m)
RoCE = -61.41% (EBIT -155.5m / Capital Employed (Equity 188.0m + L.T.Debt 65.2m))
RoIC = -56.76% (negative operating profit) (NOPAT -122.8m / Invested Capital 216.4m)
WACC = 12.32% (E(525.5m)/V(599.0m) * Re(12.20%) + D(73.5m)/V(599.0m) * Rd(16.70%) * (1-Tc(0.21)))
Discount Rate = 12.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.45%
[DCF] Fair Price = unknown (Cash Flow -126.4m)
EPS Correlation: 51.00 | EPS CAGR: 49.79% | SUE: -2.50 | # QB: 0
Revenue Correlation: 18.74 | Revenue CAGR: 8.66% | SUE: -1.79 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.28 | Chg7d=+0.161 | Chg30d=+0.161 | Revisions Net=-1 | Analysts=5
EPS current Year (2026-12-31): EPS=-2.22 | Chg7d=-0.041 | Chg30d=-0.152 | Revisions Net=-1 | Growth EPS=+41.0% | Growth Revenue=+43.9%
EPS next Year (2027-12-31): EPS=-1.88 | Chg7d=+0.103 | Chg30d=+0.077 | Revisions Net=-1 | Growth EPS=+15.3% | Growth Revenue=+27.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)